Hypercholesterolemia is an indication for drug development with over 130 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hypercholesterolemia have a 84.62% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hypercholesterolemia compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hypercholesterolemia overview
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads to the formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing a heart attack or stroke. Two forms of the condition exist: heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obesity, family history, high blood pressure, smoking, and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives, and cholesterol absorption inhibitors.
For a complete picture of PTSR and LoA scores for drugs in Hypercholesterolemia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
